Navigation Links
Innocoll Submits SPA for Cogenzia(TM) Phase III Clinical Trials for the Adjuvant Treatment of Diabetic Foot Infections
Date:7/13/2010

ASHBURN, Va., July 13 /PRNewswire/ -- Innocoll, Inc. announced that its wholly-owned subsidiary, Innocoll Technologies Ltd., has submitted a Special Protocol Assessment (SPA) for a proposed phase 3 clinical trial to support the U.S. approval of Cogenzia™:  Innocoll's topical antibiotic therapy for the adjuvant treatment of infected diabetic foot ulcers.

The protocol was developed following an End of Phase 2 meeting with FDA where the results of Innocoll's phase 2 clinical studies were presented and discussed. In the planned phase 3 randomized, placebo-controlled, double-blind clinical trial, patients with a moderate or severe diabetic foot infection will be treated with Cogenzia on a daily basis as an adjunct to standard-of-care, which includes systemic antibiotic therapy administered by the oral or intravenous route. Patients will be treated for a maximum of 28 days and the primary endpoint will be the percentage of patients who are clinically cured of infection 10 days after discontinuation of all antibiotic therapy. The study design is based on a highly encouraging phase 2 trial where 100% of Cogenzia-treated patients who completed the study achieved clinical cure, which was statistically significantly superior to 70% of patients in the control group (P = 0.024). Patients in the Cogenzia group also had a significantly higher rate of baseline pathogen eradication and a reduced time to pathogen eradication (P < 0.001).

Dr. Michael Myers, Innocoll's President and CEO commented, "Building on the strength of the phase II data, we continue to make great strides in the development of our lead product, Cogenzia.   We are particularly encouraged by the fact that the product will be developed as adjuvant therapy for use in conjunction with systemic
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
2. Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
3. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
5. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
6. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
10. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
11. Advanced Life Sciences Submits Updated Special Protocol Assessment to FDA for Restanza in Community Acquired Bacterial Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... Nov. 28, 2014  Valeant Pharmaceuticals International, Inc. ... announced that its wholly owned subsidiary, Valeant Pharmaceuticals ... of its outstanding 6.875% Senior Notes due 2018, ... on December 29, 2014 and has mailed an ... the redemption, approximately US$500 million aggregate principal amount ...
(Date:11/28/2014)... , Nov. 28, 2014 /CNW Telbec/ - Ergoresearch Ltd ... appointment of Mrs. Dominique Boudreau who will ... team. Mrs. Dominique Boudreau was acting as ... occupied similar duties for more than seven years for ... in January 2013.  Mrs. Boudreau replaces Mr. Greco who ...
(Date:11/28/2014)... Aratana Therapeutics, Inc. (NASDAQ: PETX ), ... acquisition, development and commercialization of innovative biopharmaceutical products for ... it will present at the 26 th Annual ... 2014, at the New York Palace Hotel in ... St. Peter , M.D., President and Chief Executive Officer, ...
Breaking Medicine Technology:Valeant Announces Redemption of US$445.0 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018 2Ergoresearch announces the appointment of its new Vice Président Finance 2Ergoresearch announces the appointment of its new Vice Président Finance 3Aratana Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference 2
... Measuring the body temperatures of newborns with temporal artery ... by axillary (under arm) thermometry, the clinically recommended method ... to a new study reported in Advances in ... first published clinical analysis evaluating the accuracy of temporal ...
... 18, 2011 BB&T Capital Markets served as the ... Comfort, the leading developer, manufacturer and marketer of therapeutic ... sale to DJO Global, an international provider of medical ... management based in Vista, Calif. Dr. Comfort generated net ...
Cached Medicine Technology:Study Finds Exergen Temporal Artery Thermometry Accurate on Newborns 2Study Finds Exergen Temporal Artery Thermometry Accurate on Newborns 3BB&T Advises Dr. Comfort on Its Sale to DJO Global in Transaction Valued at $254.6 Million 2
(Date:11/28/2014)... The report “Poxvirus Infections Pipeline Review ... development for Poxvirus Infections, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ... featured news and press releases. It also reviews ... Poxvirus Infections and special features on late-stage and ...
(Date:11/28/2014)... Recently, SWAccessControl.com, a renowned smartware manufacturer, has announced ... these high end products are offered at discounted rates, ... last from today to Dec 16, 2014. , The ... the promotion. We are proud of our new access ... information about our hottest items, we have listed some ...
(Date:11/28/2014)... York, NY (PRWEB) November 28, 2014 ... physical therapy techniques such as Dynamic Neuromuscular Stabilization, ... and gait/motion analysis. After moving to upgraded facilities ... and running clinic. Now, owner Dr. Lev Kalika ... performance and injury prevention lab in the country. ...
(Date:11/28/2014)... 28, 2014 (HealthDay News) -- People with diabetes face a ... help keep you healthy, an expert says. "With the ... deal with the events, the family you,ll be visiting and ... Association of Diabetes Educators, said in an association news release. ... be healthy." One idea is to make a healthy ...
(Date:11/28/2014)... Sunnyvale, CA (PRWEB) November 28, 2014 ... on December 2, 2014. This national movement was ... their communities by giving to local charities and causes. ... Thanksgiving Holiday, coincides with the kickoff of the holiday ... Friday is to shopping and Cyber Monday is to ...
Breaking Medicine News(10 mins):Health News:Poxvirus Infections and Vestibular Diseases Pipeline Market Drugs and Companies Review H2 2014 2Health News:Poxvirus Infections and Vestibular Diseases Pipeline Market Drugs and Companies Review H2 2014 3Health News:Poxvirus Infections and Vestibular Diseases Pipeline Market Drugs and Companies Review H2 2014 4Health News:New Access Control Systems Now Offered At Low Prices By Smartware Manufacturer SWAccessControl.com 2Health News:New York Dynamic Neuromuscular Rehabilitation Opens Nation's Most Advanced Movement Performance and Injury Prevention Lab 2Health News:New York Dynamic Neuromuscular Rehabilitation Opens Nation's Most Advanced Movement Performance and Injury Prevention Lab 3Health News:Holiday Eating Tips for People With Diabetes 2Health News:Pathways Home Health & Hospice Joins #GivingTuesday; Annual Holiday Encourages Local Charitable Giving 2Health News:Pathways Home Health & Hospice Joins #GivingTuesday; Annual Holiday Encourages Local Charitable Giving 3
... Group, Inc. (SSI),announced today that Siemens Healthcare has ... through SSI,s ClickON(R), ClickON(R),s LinX,offering, and content partnership., ... Healthcare customers,to take advantage of a wide range ... Status, Secondary Billing, Audit Tracking and Note,Posting for ...
... had to become a "difficult patient" before she could get ... her health. , And once the diagnosis was made, she ... "difficult" before she could get the best treatment for scleroderma, ... is a major element. , Mayer, a research assistant professor ...
... PALM BEACH, Fla., Sept 10 If a ... bag of chips or a quart of ice ... emotional eating, which can,now be helped with The ... ), the first vegan, gluten-free vitamin with human,clinical ...
... is a unique online community for people who support affordable health ... ... Columbus, OH (PRWEB) September 10, 2008 -- While politicians dispense their ... are invited to do the same online. The common place to ...
... launches a unique, national weight and stress management program based upon ... ... (PRWEB) September 10, 2008 -- With high gasoline prices, depressed real ... Americans are skyrocketing. For those that attempt to eat their stress ...
... personalized service educates clients about Medicare; identifies best options and ... ... Belleville, Ill. (Vocus) September 10, 2008 ... the services it offers to individuals with disabilities with the ...
Cached Medicine News:Health News:SSI Announces Agreement with Siemens Healthcare 2Health News:Survival instincts propel 'difficult patient' to insist on quality care 2Health News:Survival instincts propel 'difficult patient' to insist on quality care 3Health News:Stress-Related and Emotional Eating Can Be Curbed With the Vitamin Code(TM) Perfect Weight Formula 2Health News:Stress-Related and Emotional Eating Can Be Curbed With the Vitamin Code(TM) Perfect Weight Formula 3Health News:Social Network For Affordable Health Care Supporters Stimulates A New Level of Interactivity and Dialogue 2Health News:Are You A Stress Eater? Revolutionary Program Reduces Overall Stress and Stress Eating Tendencies 2Health News:Are You A Stress Eater? Revolutionary Program Reduces Overall Stress and Stress Eating Tendencies 3Health News:Allsup's New Medicare Advisor Program Helps People with Disabilities Make Sound Healthcare Coverage Decisions 2Health News:Allsup's New Medicare Advisor Program Helps People with Disabilities Make Sound Healthcare Coverage Decisions 3Health News:Allsup's New Medicare Advisor Program Helps People with Disabilities Make Sound Healthcare Coverage Decisions 4Health News:Allsup's New Medicare Advisor Program Helps People with Disabilities Make Sound Healthcare Coverage Decisions 5
... , ... event is to use an ... environment. But will the device be durable enough? Can you depend, ... its signal quality? Will the battery last? Is it comfortable, ...
... new features and state-of-the ... innovation, the SuperStim brain ... stimulation up to 30 ... and transcranial stimulation up ...
... high-volume analyzer that builds upon the field-proven ... and the latest Olympus technological advances. The ... with up to 147 on-board chemistries and ... Choose from Olympus 122 test menu, including ...
... The AU640 e is ... mid-sized to large laboratories and hospitals. ... the AU640es field-proven reliability and Olympus ... chemistries, urine chemistry, specific proteins, esoteric ...
Medicine Products: